Knight Therapeutics Inc. provided revenue guidance for the fiscal year 2024. For the period, the company expected to generate revenues between $335 million to $350 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.86 CAD | +2.09% | -0.17% | +12.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.91% | 433M | |
+13.33% | 9.15B | |
+48.35% | 4.65B | |
-20.52% | 4.58B | |
+7.99% | 4.07B | |
+8.69% | 2.24B | |
-25.72% | 2.21B | |
+12.16% | 2.03B | |
-41.98% | 1.82B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024